8-K: Annexon's ANX005 Achieves Positive Topline Results in Phase 3 GBS Trial, Showing Significant Improvement

Annexon's ANX005 demonstrated a statistically significant 2.4-fold improvement on the GBS-disability scale in a Phase 3 trial for Guillain-Barré syndrome.

Summary

• Annexon announced positive topline results from its Phase 3 clinical trial for ANX005 in patients with Guillain-Barré syndrome (GBS).
• The trial met its primary endpoint, with a single 30 mg/kg infusion of ANX005 showing a statistically significant 2.4-fold improvement on the GBS-disability scale at week 8.
• ANX005 also demonstrated improvements in key secondary endpoints, including early gains in muscle strength, a reduction in time on artificial ventilation by a median of 28 days, and a 31-day reduction in the median time to walk independently.
• The 30 mg/kg dose of ANX005 resulted in one week of C1q inhibition, which appeared to be the optimal treatment window.
• The trial enrolled 241 subjects in Bangladesh and the Philippines and evaluated two doses of ANX005, 30 mg/kg and 75 mg/kg.
• The 75 mg/kg dose did not achieve statistical significance on the primary endpoint.
• The safety profile of ANX005 was generally well-tolerated, with most adverse events being mild to moderate infusion-related reactions.
• Annexon has initiated a real-world evidence protocol to establish comparability between Phase 3 participants and Western patients, with data and a potential biologics license application submission expected in the first half of 2025.
• GBS is a severe neurological disease that results in the hospitalization of over 22,000 people annually in the U.S. and Europe, with no currently approved treatments by the FDA.

Sentiment

Score: 9

Explanation: The document presents highly positive results from a Phase 3 trial, with statistically significant improvements in key endpoints and a good safety profile. The potential for ANX005 to be the first approved treatment for GBS is a major positive, and the company has a clear path to regulatory submission.

Positives

• The Phase 3 trial met its primary endpoint with a statistically significant improvement in GBS-DS.
• ANX005 demonstrated early and sustained improvements in key secondary endpoints, including muscle strength and time on ventilation.
• The treatment showed a reduction in nerve damage biomarkers.
• ANX005 was generally well-tolerated with no new safety signals.
• The study results are consistent with earlier Phase 1b findings.
• The 30 mg/kg dose of ANX005 showed a clear benefit, defining the optimal treatment window.
• The study was conducted in a region with a high prevalence of GBS, providing relevant data.
• The company has initiated a real-world evidence protocol to support regulatory submission.
• ANX005 has been granted Fast Track and Orphan Drug Designations from the FDA and Orphan Drug Designation by the EMA.

Negatives

• The 75 mg/kg dose of ANX005 did not achieve statistical significance on the primary endpoint.
• Infusion-related reactions were the most common treatment-related adverse events, although mostly mild.
• The study was conducted in Bangladesh and the Philippines, requiring a real-world evidence study to establish comparability with Western patients.

Risks

• The 75 mg/kg dose of ANX005 did not meet the primary endpoint, indicating a potential risk in dose selection.
• The need for a real-world evidence study to establish comparability with Western patients introduces a potential delay and uncertainty in regulatory approval.
• The company is still in the process of obtaining regulatory approval and commercializing its product candidates.
• There are risks associated with the company's reliance on third-party suppliers and manufacturers.
• The company has a history of net operating losses and needs to obtain necessary capital to fund its clinical programs.
• There are risks associated with the early stages of clinical development of the company's product candidates.
• The company's ability to maintain intellectual property rights for its product candidates is a risk.

Future Outlook

The company anticipates submitting a Biologics License Application (BLA) to the FDA in the first half of 2025, supported by real-world evidence data. They also plan to continue advancing their mid-to late-stage clinical trials.

Management Comments

• Douglas Love, president and chief executive officer of Annexon, stated that the data represent an important moment for the GBS community and Annexon.
• He also noted that ANX005 demonstrated consistent improvement and functional benefits on key primary and secondary endpoints.
• Hugh Willison, MBBS, PhD, Professor Emeritus of Neurology, University of Glasgow, said that ANX005 demonstrated robust and immediate neuroprotection by inhibiting C1q.
• David Cornblath, MD, Professor Emeritus of Neurology, Johns Hopkins University School of Medicine, stated that the study demonstrated that acute and early intervention with ANX005 can deliver clinical benefits across the entire GBS disease spectrum.

Industry Context

This announcement is significant as there are currently no FDA-approved treatments for GBS, a disease with a substantial impact on patients and healthcare systems. The positive results for ANX005 position it as a potential first-in-class treatment for this condition.

Comparison to Industry Standards

• The study is the first placebo-controlled pivotal study in GBS in approximately 40 years, highlighting the lack of recent advancements in this area.
• The results of ANX005 are compared to the current standard of care, intravenous immunoglobulin (IVIg), which is not FDA approved for GBS and has an unknown mechanism of action.
• The study design is rigorous, including stratification by prognostic factors and the use of a proportional odds model for analysis, which is a common statistical method.
• The study is compared to a Phase 3 trial of Eculizumab, which targets downstream complement (C5) and misses important upstream drivers of nerve damage, highlighting the potential advantage of ANX005's mechanism of action.
• The study results are compared to the International Guillain-Barr Syndrome Outcomes Study (IGOS) to establish comparability between Phase 3 participants and Western patients.

Stakeholder Impact

• Shareholders are likely to react positively to the successful Phase 3 trial results.
• Patients with GBS and their families stand to benefit from a potential new treatment option.
• Healthcare providers may have a new tool to manage GBS, potentially reducing the burden on hospitals and healthcare systems.
• The company's employees and collaborators are likely to be motivated by the positive results.

Next Steps

• Annexon plans to present the Phase 3 data at the 2024 Peripheral Nerve Society Annual Meeting on June 25, 2024.
• The company will continue its real-world evidence protocol with the International Guillain-Barr Syndrome Outcomes Study.
• Annexon is preparing for a potential biologics license application submission with the FDA in the first half of 2025.
• The company is preparing a focused commercial launch strategy.

Key Dates

Keywords

ANX005, Guillain-Barré syndrome, GBS, Phase 3 trial, C1q inhibition, neuroinflammation, neurological disease, biopharmaceutical, clinical trial, FDA, real-world evidence, RWE, complement cascade, nerve damage, muscle strength, artificial ventilation